Level of evidence of irinotecan clinical trials and recent data in colorectal cancer

Wolmark, 1993, The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03, J. Clin. Oncol., 11, 1879, 10.1200/JCO.1993.11.10.1879 Meta-analysis Group in Cancer. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10, 896–903 O'Connell, 1997, Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer, J. Clin. Oncol., 15, 246, 10.1200/JCO.1997.15.1.246 de Gramont, 1997, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study, J. Clin. Oncol., 15, 808, 10.1200/JCO.1997.15.2.808 Köhne, 2003, J. Clin. Oncol., 21, 3721, 10.1200/JCO.2003.11.122 de Gramont, 1998, A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouraci l48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD), Eur. J. Cancer, 34, 619, 10.1016/S0959-8049(97)00364-X Rougier, 1998, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer, Lancet, 352, 1407, 10.1016/S0140-6736(98)03085-2 Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N. Engl. J. Med., 343, 905, 10.1056/NEJM200009283431302 Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 Cunningham, 1998, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, Lancet, 352, 1413, 10.1016/S0140-6736(98)02309-5 de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J. Clin. Oncol., 18, 2938, 10.1200/JCO.2000.18.16.2938 Grothey, 2001, Bolus 5-fluorouracil (5-FU)/ folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/FA+oxaliplatin (OXA) in advanced colorectal cancer (CRC). Results of a phase III study, Proc. Am Soc. Clin. Oncol., 20 Giacchetti, 2000, Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer, J. Clin. Oncol., 18, 136, 10.1200/JCO.2000.18.1.136 NCI. Levels of evidence for adult cancer treatment studies 2003. Available from: www.cancer.gov Köhne, 2003, Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of the EORTC GI Group study 40986, Proc. Am Soc. Clin. Oncol., 22 Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J. Clin. Oncol., 22, 23, 10.1200/JCO.2004.09.046 Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study, J. Clin. Oncol., 22, 229, 10.1200/JCO.2004.05.113